In recent trading session, LAVA Therapeutics NV (NASDAQ:LVTX) saw 0.44 million shares changing hands at last check today with its beta currently measuring 0.55. Company’s recent per share price level of $0.98 trading at -$0.04 or -4.41% at last check today assigns it a market valuation of $25.64M. That most recent trading price of LVTX’s stock is at a discount of -560.2% from its 52-week high price of $6.47 and is indicating a premium of 10.2% from its 52-week low price of $0.88. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.13 million shares which gives us an average trading volume of 107.24K if we extend that period to 3-months.
For LAVA Therapeutics NV (LVTX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.27 in the current quarter.
LAVA Therapeutics NV (NASDAQ:LVTX) trade information
Upright in the red during last session for losing -4.41%, in the last five days LVTX remained trading in the red while hitting it’s week-highest on Tuesday, 01/07/25 when the stock touched $0.98 price level, adding 12.5% to its value on the day. LAVA Therapeutics NV’s shares saw a change of 2.52% in year-to-date performance and have moved -5.34% in past 5-day. LAVA Therapeutics NV (NASDAQ:LVTX) showed a performance of -48.95% in past 30-days. Number of shares sold short was 26439.0 shares which calculate 0.41 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 83.67% to its recent value today. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -512.24% in reaching the projected high whereas dropping to the targeted low would mean a loss of -512.24% for stock’s current value.
LAVA Therapeutics NV (LVTX) estimates and forecasts
Statistics highlight that LAVA Therapeutics NV is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -45.53% of value to its shares in past 6 months, showing an annual growth rate of 28.03% while that of industry is 16.50. Apart from that, the company came raising its revenue forecast for fiscal year 2025. This year revenue growth is estimated to rise 18.89% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 2.4M for the same. Company posted 325.04k and 6.44M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 86.55% during past 5 years.
LAVA Therapeutics NV (NASDAQ:LVTX)’s Major holders
REDMILE GROUP, LLC is the top institutional holder at LVTX for having 2.07 million shares of worth $3.73 million. And as of 2024-06-30, it was holding 7.7419 of the company’s outstanding shares.
The second largest institutional holder is BRUCE & CO., INC., which was holding about 0.77 million shares on 2024-06-30. The number of shares represents firm’s hold over 2.8807 of outstanding shares, having a total worth of $1.39 million.
On the other hand, Bruce & Co., Inc. and Fidelity NASDAQ Composite Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024, the former fund manager was holding 771.87 shares of worth $0.75 million or 2.94% of the total outstanding shares. The later fund manager was in possession of 11.12 shares on Nov 30, 2024, making its stake of worth around $10791.0 in the company or a holder of 0.04% of company’s stock.
